126 related articles for article (PubMed ID: 16557022)
21. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
[TBL] [Abstract][Full Text] [Related]
22. C-reactive protein as predictor of death in end-stage diabetic nephropathy: role of peripheral arterial disease.
Böger CA; Götz A; Stubanus M; Banas B; Deinzer M; Krüger B; Holmer SR; Schmitz G; Riegger GA; Krämer BK
Kidney Int; 2005 Jul; 68(1):217-27. PubMed ID: 15954911
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Patrick L; Uzick M
Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients.
Perunicic-Pekovic G; Pljesa S; Rasic-Milutinovic Z; Stankovic S; Ilic M; Maletic R
Can J Physiol Pharmacol; 2008 Apr; 86(4):205-9. PubMed ID: 18418430
[TBL] [Abstract][Full Text] [Related]
25. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
26. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes.
Yilmaz MI; Stenvinkel P; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Altun B; Yenicesu M; Carrero JJ
Nephrol Dial Transplant; 2011 Nov; 26(11):3537-43. PubMed ID: 21378154
[TBL] [Abstract][Full Text] [Related]
27. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.
Kaysen GA; Levin NW; Mitch WE; Chapman AL; Kubala L; Eiserich JP
Blood Purif; 2006; 24(5-6):508-16. PubMed ID: 17077623
[TBL] [Abstract][Full Text] [Related]
28. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study.
Kessler M; Zannad F; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P;
Nephrol Dial Transplant; 2007 Dec; 22(12):3573-9. PubMed ID: 17611249
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
Piechota W; Piechota W
Pol Merkur Lekarski; 2005 May; 18(107):511-5. PubMed ID: 16161944
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein predicts vascular access thrombosis in hemodialysis patients.
Chou CY; Kuo HL; Yung YF; Liu YL; Huang CC
Blood Purif; 2006; 24(4):342-6. PubMed ID: 16601326
[TBL] [Abstract][Full Text] [Related]
31. Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients.
Mutluay R; Konca C; Erten Y; Paşaoğlu H; Değer SM; Ağirgün C; Derici U; Arinsoy T; Sindel S
Ren Fail; 2010 May; 32(4):448-54. PubMed ID: 20446782
[TBL] [Abstract][Full Text] [Related]
32. Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up.
Desideri G; Panichi V; Paoletti S; Grassi D; Bigazzi R; Beati S; Bernabini G; Rosati A; Ferri C; Taddei S; Ghiadoni L;
Nephrol Dial Transplant; 2011 Sep; 26(9):2983-8. PubMed ID: 21303961
[TBL] [Abstract][Full Text] [Related]
33. C- Reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients.
Bagheri N; Taziki O; Falaknazi K
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):789-93. PubMed ID: 19736474
[TBL] [Abstract][Full Text] [Related]
34. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
[TBL] [Abstract][Full Text] [Related]
35. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
36. C-reactive protein (CRP)-lowering agents.
Prasad K
Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
[TBL] [Abstract][Full Text] [Related]
37. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
Dummer CD; Thome' FS; Zingano B; Lindoso A; Veronese FV
J Nephrol; 2008; 21(6):900-8. PubMed ID: 19034875
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein and uremia.
Wanner C; Drechsler C; Krane V
Semin Dial; 2009; 22(4):438-41. PubMed ID: 19708997
[TBL] [Abstract][Full Text] [Related]
39. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
Chang JW; Yang WS; Min WK; Lee SK; Park JS; Kim SB
Am J Kidney Dis; 2002 Jun; 39(6):1213-7. PubMed ID: 12046033
[TBL] [Abstract][Full Text] [Related]
40. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
